Stuttgart
09.01.26 | 20:32
1,656 Euro
-3,27 % -0,056
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 04.11.25 | Advicenne Has Submitted to US FDA the Registration Application for Sibnayal in dRTA Treatment | 386 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from... ► Artikel lesen | |
| 04.11.25 | ADVICENNE: Advicenne has submitted to the US FDA the registration application (NDA) for Sibnayal in dRTA treatment | 3 | Euronext | ||
| 07.10.25 | ADVICENNE: Advicenne reports First Half financial results as of June 30, 2025, and updates on its activities | 3 | Euronext | ||
| 19.09.25 | Advicenne Reports First Half Financial Results as of June 30, 2025, and Updates on Its Activities | 434 | Business Wire | Sibnayal® end-market sales (Europe and Middle East) up 103% to €5.5 million
H1 products sales and royalties totaled €3.1 million, up 20%
Financial visibility extended to the fourth... ► Artikel lesen | |
| 26.08.25 | Advicenne Announces the Publication in Orphanet Journal of Rare Diseases of the Long-term European Study Results of dRTA Treatment Using ADV7103 | 333 | Business Wire | This extensive clinical dataset serves ADV7103 registration dossier in the United States of America, expected to be submitted in Q4 2025
Regulatory News:
Advicenne (Euronext Growth Paris... ► Artikel lesen | |
| 28.07.25 | Advicenne Receives Marketing Authorization and Reimbursement for Sibnayal in Saudi Arabia | 459 | Business Wire | Regulatory News:
Advicenne (Euronext Growth® FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare... ► Artikel lesen | |
| 25.07.25 | Advicenne Reports its H1 2025 Sales | 410 | Business Wire | Regulatory News:
Advicenne (Euronext Growth FR0013296746 ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney... ► Artikel lesen | |
| 21.07.25 | Advicenne Raises 2.6 Million Euros in Its Capital Increase and Extends Its Financial Visibility | 822 | Business Wire | Subscription of €2.6 million, representing 100% of the initial amount Financial horizon extended to the end of Q3 2026 thanks to concomitant financial restructuring Bpifrance now... ► Artikel lesen | |
| 02.07.25 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.07.2025 | 403 | Xetra Newsboard | Das Instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY wird ex Kapitalmassnahme gehandelt am 02.07.2025 The instrument 3MM FR0013296746 ADVICENNE (PROM.) EO-,20 EQUITY is traded ex capital... ► Artikel lesen | |
| 30.06.25 | Advicenne Confirms the Upcoming Filing for Registration of ADV7103 in the USA and is Securing Its Financing Through Loan Restructuring and the Launch of a Rights Issue. | 435 | Business Wire | Submission of the US marketing authorization application for ADV7103 planned in Q4 2025, following positive feedback from the FDA on the additional data submitted. Repayment of tranches... ► Artikel lesen | |
| 29.04.25 | Advicenne 2024 Universal Registration Document Made Available | 336 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 27.03.25 | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 615 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| 29.01.25 | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 530 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01.25 | Advicenne Announces 2024 Gross Sales1 | 521 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,900 | +0,94 % | mRNA Patentstreit: Bayer zieht BioNTech, Pfizer und Moderna vor Gericht | © Foto: Juan Vega - EUROPA PRESSBayer erhebt schwere Patentvorwürfe gegen die Hersteller der erfolgreichsten Corona-Impfstoffe. Im Zentrum steht eine mRNA-Technologie aus den 1980er-Jahren.Der Agrar-... ► Artikel lesen | |
| ABBVIE | 189,60 | -1,46 % | Börsenfrühstück: Defense, AbbVie, Micron & Exxon | Marktbeicht für den 08.01.2026: Die internationalen Aktienmärkte zeigen sich nach dem starken Jahresstart uneinheitlich. In den USA schloss der S&P 500 am Mittwoch leicht im Minus, während der Nasdaq... ► Artikel lesen | |
| HAEMATO | 8,750 | -2,78 % | EQS-Adhoc: M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group
16.10.2025... ► Artikel lesen | |
| HALEON | 4,260 | -1,11 % | Haleon announces new chief growth officer role, creates six operating units | ||
| LIGAND PHARMACEUTICALS | 174,00 | +2,35 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 4,615 | -1,81 % | Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program | One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025... ► Artikel lesen | |
| ROYALTY PHARMA | 34,950 | +1,19 % | Royalty Pharma plc: Royalty Pharma Announces Dividend Increase | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class... ► Artikel lesen | |
| EISAI | 26,910 | +3,50 % | Newron Pharmaceuticals S.p.A.: EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan | Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral... ► Artikel lesen | |
| TG THERAPEUTICS | 24,765 | -5,42 % | TG Therapeutics, Inc.: TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI | NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated... ► Artikel lesen | |
| DR REDDYS | 11,300 | 0,00 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| BETTERLIFE PHARMA | 0,026 | +18,18 % | BetterLife Pharma Inc.: BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco | Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 12,100 | -4,72 % | Raymond James raises WAVE Life Sciences stock price target to $26 | ||
| KYOWA KIRIN | 14,000 | +0,72 % | Dividendenbekanntmachungen (29.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADWAYS INC JP3121970002 6,35 JPY 0,0344 EUR AGC INC JP3112000009 105 JPY 0,5701 EUR AMERICAN TOWER CORPORATION US03027X1000 1... ► Artikel lesen | |
| IGC PHARMA | 0,256 | -3,76 % | IGC Pharma, Inc.: IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability | POTOMAC, MD / ACCESS Newswire / January 6, 2026 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage pharmaceutical company leveraging Artificial Intelligence... ► Artikel lesen | |
| IMMUPHARMA | 0,063 | -5,26 % | Immupharma PLC - Attending JPMorgan Conference & Biotech Showcase |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.